Sign in

CIK 0001626971 · Non-accelerated filer<br>Smaller reporting company

Corvus Pharmaceuticals, Inc.

Sign in to watch
Ticker
CRVS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
464670809
Phone
(650) 900-4520
Business address
901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA, 94080
  1. 10-Q Report Quarterly Report
  2. 8-K Event Results of operations
  3. DEFA14A Proxy Proxy Materials
  4. DEF 14A Proxy Proxy Statement
  5. 4 Open-market buy President and CEO bought 15,000 shares at $1.64 ($24,534)
  6. 4 Open-market buy Chief Financial Officer bought 49,038 shares at an average $1.57 ($77,045)
  7. 4 Open-market buy President and CEO bought 30,000 shares at an average $1.49 ($44,600)
  8. 10-K Report Annual Report
  9. 8-K Event Results of operations
  10. SC 13G/A Stake Amended Statement of Ownership
  11. SC 13G/A Stake Amended Statement of Ownership
  12. SC 13G/A Stake Amended Statement of Ownership
  13. SC 13G/A Stake Amended Statement of Ownership
  14. SC 13G/A Stake Amended Statement of Ownership
  15. SC 13G Stake Amended Statement of Ownership
  16. SC 13D/A Stake Beneficial Ownership Report
  17. 8-K Event Material agreement
  18. 424B5 Offering Prospectus
  19. 10-Q Report Quarterly Report
  20. 8-K Event Results of operations

Page 11 of 30 · 584 filings